Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fulgent GeneticsFLGT +3.05%69 Earnings per Share (Diluted) is $-2.82 as of Jun. 2026. GuruFocus rates FLGT with a GF Score™ of 69/100 and a GF Value™ of $24.44 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 161 Medical Diagnostics & Research companies, Fulgent Genetics ranks worse than 94.41% on this metric.
Fulgent Genetics's EPS (Basic) for the
three
months ended in Jun. 2026 was $-1.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.82.
During the past 12 months, Fulgent Genetics's average EPS without NRIGrowth Rate was -2960.00% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -58.30% per year.
During the past 12 years, Fulgent Genetics's highest 3-Year average EPS without NRI Growth Rate was 212.40% per year. The lowest was -69.10% per year. And the median was 27.30% per year.
Fulgent Genetics (NAS:FLGT) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Fulgent Genetics Earnings per Share (Diluted) Related Terms
Fulgent Genetics Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics Earnings per Share (Diluted) Chart
FLGT vs MYGN, BDSX, XGN: Earnings per Share (Diluted) Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's PE Ratio falls into.
Fulgent Genetics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Fulgent Genetics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-2.82 mean?
Fulgent Genetics (FLGT) has a Earnings per Share (Diluted) of $-2.82 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Fulgent Genetics and its competitors. According to the industry distribution chart, Fulgent Genetics ranks #152 out of 161 companies in the Medical Diagnostics & Research industry, placing it in the top 94.4%.
Is Fulgent Genetics' Earnings per Share (Diluted) too high?
Fulgent Genetics' current Earnings per Share (Diluted) is $-2.82. Based on the distribution chart, Fulgent Genetics ranks #152 out of 161 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Fulgent Genetics has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Earnings per Share (Diluted) compare to MYGN and BDSX?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #152 out of 161 companies for Earnings per Share (Diluted). This places Fulgent Genetics in the lower half of its industry. The industry median Earnings per Share (Diluted) is 10.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Diagnostics & Research company?
The median Earnings per Share (Diluted) among Medical Diagnostics & Research companies is 10.70, based on 161 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Fulgent Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Earnings per Share (Diluted) is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current Earnings per Share (Diluted) is $-2.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $24.44, compared to a current price of $21.28 — trading 12.9% below its estimated fair value. The current Earnings per Share (Diluted) is $-2.82. Fulgent Genetics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Earnings per Share (Diluted) is $-2.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $21.28 is trading 12.9% below its estimated GF Value™ of $24.44.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
Earnings per Share (Diluted): $-2.82
GF Value™: $24.44 vs. price of $21.28 (12.9% below fair value)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
69GF Score
Get the complete analysis for FLGT
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
